Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Benjamin Garden

Dermatology Skokie, IL Medical Doctor

NPI 1699193334 CMS profile 2780987

4605 Golf Rd, Skokie, IL 60076

Open in the dashboard

General payments

$21,857

208 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Garden of Skokie, IL is reported in the CMS Open Payments database as having received $21,857 across 208 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,582 80
2024 General $968 53
2023 General $8,249 41
2022 General $10,611 15
2021 General $108 6
2020 General $107 5
2019 General $231 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Garden
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Benjamin Garden were reported at $1,582. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Benjamin Garden Dermatology median Middle half National median
2019 $231 $454 $129–$1,240 $163
2020 $107 $235 $81–$756 $114
2021 $108 $377 $108–$1,108 $132
2022 $10,611 $514 $143–$1,391 $149
2023 $8,249 $607 $159–$1,674 $160
2024 $968 $751 $204–$1,903 $164
2025 $1,582 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $18,734 63 payments
  2. Janssen Biotech, Inc. $813 51 payments
  3. Genzyme Corporation $699 24 payments
  4. AbbVie, Inc. $605 26 payments
  5. Galderma Laboratories, L.P. $274 17 payments
  6. Regeneron Healthcare Solutions, Inc. $196 5 payments
  7. Allergan Inc. $97 1 payment
  8. Novartis Pharmaceuticals Corporation $70 4 payments
  9. MIMEDX Group, Inc. $48 2 payments
  10. UCB, Inc. $47 2 payments
  11. Other $274 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,625 11 payments
  2. Food and Beverage $3,887 189 payments
  3. Education $210 3 payments
  4. Travel and Lodging $135 5 payments
Products named General payments · program years 2019–2025
  1. TALTZ $18,305 57 payments
  2. DUPIXENT Immunology $878 27 payments
  3. TREMFYA $813 51 payments
  4. EBGLYSS $328 19 payments
  5. RINVOQ $285 10 payments
  6. OLUMIANT $159 6 payments
  7. SKYRIZI Immunology $151 8 payments
  8. NEMLUVIO $148 10 payments
  9. SKYRIZI Immunology $118 6 payments
  10. DUPIXENT Inflammation And Immunology $102 4 payments
  11. Other $622 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,250

Median for Dermatology: 534

Drug cost

$292,540

Median for Dermatology: $67,151

Branded share of claims

23.8%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 25 $99,420
Abrysvo Rsv Vacc, Pref A And Pref B/Pf Brand 261 $82,055
Cosentyx (2 Syringes) Secukinumab Brand 12 $81,622
Fluocinonide Generic 142 $6,846
Clobetasol Propionate Generic 69 $4,842
Ketoconazole Generic 199 $4,726
Betamethasone Dipropionate Generic 66 $4,067
Triamcinolone Acetonide Generic 227 $2,554
Metronidazole Generic 39 $1,893
Tacrolimus Generic 15 $1,198

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$572,557

Of which drugs: $261,710

Medicare patients

1,847

Average age 74

Services billed

6,883

983 women, 864 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 55%
Alzheimer's or dementia 45%
Arthritis 44%
Diabetes 41%
COPD 34%
Chronic kidney disease 31%
Ischemic heart disease 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 667 667 $105,651
Pcv20 vaccine im 90677 Office 256 256 $74,772
Vaccine for influenza for injection into muscle 90653 Office 657 657 $53,756
Sarscv2 vac 30mcg trs-suc im 91320 Office 147 147 $22,459
Influenza vaccine, trivalent derived from cell cultures 90661 Office 140 140 $5,055
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 16 25 $17

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $293
$293 — —
DUPIXENT
  • GENZYME CORPORATION $141
  • Regeneron Healthcare Solutions, Inc. $102
$243 25 —
SKYRIZI
  • AbbVie, Inc. $86
$86 — —
TALTZ
  • Lilly USA, LLC $39
$39 — —
Klisyri
  • Almirall LLC $26
$26 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

208 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record